The Doctrine of Double Effect, Deadly Drugs, and Business Ethics
Manuel Velasquez and F. Neil Brady apply the doctrine of double effect to business ethics and conclude that the doctrine allows a pharmaceutical company to sell a drug with potentially fatal side effects only if it also has the good effect of saving lives. This forbids the sale of many common produc...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Interlibrary Loan: | Interlibrary Loan for the Fachinformationsdienste (Specialized Information Services in Germany) |
| Published: |
2000
|
| In: |
Business ethics quarterly
Year: 2000, Volume: 10, Issue: 2, Pages: 483-495 |
| Online Access: |
Volltext (JSTOR) Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
| Summary: | Manuel Velasquez and F. Neil Brady apply the doctrine of double effect to business ethics and conclude that the doctrine allows a pharmaceutical company to sell a drug with potentially fatal side effects only if it also has the good effect of saving lives. This forbids the sale of many common products, such as automobiles and alcohol. My account preserves the virtues of the doctrine of double effect without making it too restrictive. I apply the doctrine to a pharmaceutical company’s decision to market a drug with dangerous side effects and argue that free markets often offer the best way to compare the good and bad effects of business decisions. I conclude that the doctrine does allow a business to sell a potentially fatal product that does not save lives, provided that it warns consumers about the danger. |
|---|---|
| ISSN: | 2153-3326 |
| Contains: | Enthalten in: Business ethics quarterly
|
| Persistent identifiers: | DOI: 10.2307/3857887 |